<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01241383</url>
  </required_header>
  <id_info>
    <org_study_id>P081217</org_study_id>
    <nct_id>NCT01241383</nct_id>
  </id_info>
  <brief_title>Effect of Bosentan in Scleroderma Renal Crisis</brief_title>
  <acronym>ScS-REINBO</acronym>
  <official_title>Effect of Bosentan in the Course of Scleroderma Renal Crisis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis (SSc) is a connective tissue disease characterized by excessive collagen&#xD;
      deposition, autoimmunity and by vascular hyper-reactivity and obliterative microvascular&#xD;
      phenomena that involves multiple organs. Scleroderma Renal Crisis (SRC) occurs in 5% of&#xD;
      patients and mainly with diffuse cutaneous SSc. The routine use of angiotensin-converting&#xD;
      enzyme inhibitors (ACEI) has been reported to dramatically improve outcome, with a fall of&#xD;
      the 12-month mortality from 76% to less than 15% in the United-States. Despite prognostic&#xD;
      improvement, SRC remains a severe manifestation of SSc and functional outcome and survival&#xD;
      remains poor. Bosentan is a specific, orally active, dual endothelin receptor antagonist that&#xD;
      has recently been approved for the treatment of primary pulmonary arterial hypertension and&#xD;
      for the prevention of ischemic digital ulcers. Bosentan could have therapeutic benefits on&#xD;
      others vascular injuries and particularly in SRC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic sclerosis (SSc) is a connective tissue disease characterized by excessive collagen&#xD;
      deposition, autoimmunity and by vascular hyper-reactivity and obliterative microvascular&#xD;
      phenomena that involves multiple organs. Scleroderma Renal Crisis (SRC) occurs in 5% of&#xD;
      patients and mainly with diffuse cutaneous SSc. The routine use of angiotensin-converting&#xD;
      enzyme inhibitors (ACEI) has been reported to dramatically improve outcome, with a fall of&#xD;
      the 12-month mortality from 76% to less than 15% in the United-States. Despite prognostic&#xD;
      improvement, SRC remains a severe manifestation of SSc and functional outcome and survival&#xD;
      remains poor. Bosentan is a specific, orally active, dual endothelin receptor antagonist that&#xD;
      has recently been approved for the treatment of primary pulmonary arterial hypertension and&#xD;
      for the prevention of ischemic digital ulcers. Bosentan could have therapeutic benefits on&#xD;
      others vascular injuries and particularly in SRC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To explore the efficacy of bosentan (Tracleer) in patients with scleroderma renal crisis on renal function</measure>
    <time_frame>6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of bosentan in patients with scleroderma renal crisis over 6 months of treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Scleroderma Renal Crisis</condition>
  <arm_group>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <description>Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks</description>
    <arm_group_label>Bosentan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women ≥ 18 years&#xD;
&#xD;
          -  Patients had to fulfil ACR and/or LEROY et MEDSGER criteria for systemic sclerosis&#xD;
&#xD;
          -  Patients had to fulfil criteria for renal systemic sclerosis&#xD;
&#xD;
          -  Written informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Scleroderma renal crisis occuring before the age of eighteen&#xD;
&#xD;
          -  Patients who are receiving bosentan within one month of inclusion for pulmonary&#xD;
             arterial hypertension or digital ulcers prevention&#xD;
&#xD;
          -  Other treatment by selective or nonselective antagonist endothelin receptor&#xD;
&#xD;
          -  Left ventricle systolic dysfunction (EF &lt; 40 %)&#xD;
&#xD;
          -  Patients with systolic blood pressure &lt; 85mm Hg&#xD;
&#xD;
          -  Progressive cancer or considered cured for less than 5 years&#xD;
&#xD;
          -  Patients with a known hypersensitivity to bosentan or any of the excipients&#xD;
&#xD;
          -  Patients with HIV, HCV, HBV infection&#xD;
&#xD;
          -  Patients with Liver disease Child-Pugh B and C&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding&#xD;
&#xD;
          -  Women of child-bearing age who are sexually active without practising reliable methods&#xD;
             of contraception&#xD;
&#xD;
          -  Patients who do not give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice BEREZNE, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pôle de médecine interne Centre de référence Maladies rares Groupe I Maladies systémiques et maladies auto-immunes rares en particulier Vascularites nécrosantes et les sclérodermies - Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>November 12, 2010</study_first_submitted>
  <study_first_submitted_qc>November 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <last_update_submitted>July 5, 2016</last_update_submitted>
  <last_update_submitted_qc>July 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scleroderma renal crisis</keyword>
  <keyword>angiotensin converting enzyme inhibitors</keyword>
  <keyword>bosentan</keyword>
  <keyword>endothelin receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

